Podium to Practice: Chicago 2026 – MELANOMA: PRAME-directed TCR T-cell therapy
OR
Studies / Trials Discussed
9508 – Patient-level clinical response dynamics in advanced melanoma with anzutresgene autoleucel (anzu-cel), a PRAME-directed T-cell receptor (TCR) T-cell therapy.
Chair
Speakers
Explore more from your favourite experts – click their name to access their entire library of content.
Studies/trials discussed:
9508 – Patient-level clinical response dynamics in advanced melanoma with anzutresgene autoleucel (anzu-cel), a PRAME-directed T-cell receptor (TCR) T-cell therapy.
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.